Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma.

ABSTRACT:

Introduction

Variability in response to atezolizumab plus bevacizumab (AB) treatment of hepatocellular carcinoma (HCC) underscores the critical need for the development of effective biomarkers. We sought to identify peripheral blood biomarkers reflecting response to AB treatment.

Methods

We analyzed dynamic changes in peripheral blood mononuclear cells from a prospective, multicenter cohort of 65 patients with HCC, using flow cytometry to evaluate the T-cell population before and 3 weeks after the first AB treatment.

Results

We found a unique response of the CD8⁺ T cells in terms of both frequency and phenotype, in contrast to CD4⁺ T cells and regulatory T cells. Notably, CD8⁺ T cells showed significant changes in expression of Ki-67 a

SUBMITTER: Han JW 

PROVIDER: S-EPMC11936438 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature